Phenomenex’s CEO Fasha Mahjoor has announced $12 million in bonuses for the company’s staff following the sale of Phenomenex Inc. to Danaher Corporation in October 2016.
Phenomenex’s CEO Fasha Mahjoor has announced $12 million in bonuses for the company’s staff following the sale of Phenomenex Inc. to Danaher Corporation in October 2016.
Chief Executive Fasha Mahjoor, who owns 90% of Phenomenex and founded the company in 1982, will continue on as President following the sale, which some reports have estimated to be in the $700 million region.
Mahjoor discussed the sale of his company in October stating, “Joining Danaher will allow us to maintain the high pace of innovation that our customers and international distributors have come to expect from us. This is our opportunity to further expand our R&D activities, benefit our customers with a more diversified product portfolio, and reinforce our market leadership.”
Approximately 95% of Phenomenex’s 800-strong workforce are likely to benefit from this announcement, although exact payouts are to be determined on service. The deal also maintains Phenomenex as a standalone company, while simultaneously increasing links with Sciex, another Danaher-owned chromatography business that Phenomenex collaborate with regularly.
“We are thrilled to have Phenomenex join Danaher’s life sciences portfolio of businesses, which includes Sciex, Beckman Coulter Life Sciences, Pall, Leica Microsystems, and Molecular Devices,” said Dan Daniel, Executive Vice President of Danaher Corporation.
“Phenomenex is a strong business characterized by high growth rates and margins, and excellent growth prospects driven by increasing analytical testing needs in the health, research, and environmental segments,” continued Daniel.
“We look forward to supporting the Phenomenex team and welcoming them to our Life Sciences team.”
For more information please visit: www.phenomenex.com or www.danaher.com
Determining Neurotransmitters in Spinal Cords with UHPLC
February 18th 2025Researchers at Jilin University (Changchun, China) developed a highly sensitive, rapid, and accurate method for analyzing neurotransmitters (NTs) in rat spinal cord tissue. Ultra-high performance liquid chromatography-triple quadrupole tandem mass spectrometry (UHPLC-QqQ-MS/MS) in conjunction with ultra-ionic liquid dispersive liquid-liquid microextraction (UA-MIL-DLLME) were used to extract NTs for analysis.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
Revolutionizing LC-MS with Next-Gen Separation for Cyclic Peptide Analysis
February 17th 2025Cyclic peptides, known for their stability and high specificity, are promising therapeutic agents in the fight against cancer, infections, and autoimmune diseases. However, developing effective cyclic peptides presents numerous challenges, including poor pharmacokinetics, efficacy, and toxicity. Traditional methods like liquid chromatography tandem-mass spectrometry (LC-MS/MS) often struggle with resolving isomeric linear peptide metabolites, posing significant risks in safety, efficacy, and regulatory approval. In this paper, Komal Kedia, PhD, will share how she leveraged MOBIE’s high-resolution ion mobility-mass spectrometry (IM-MS) system to achieve a 72% reduction in run times, 200% greater resolving power, and enhanced accuracy in identifying “soft spots” prone to enzymatic degradation.